Senate, December 27, 2024 -- Report of the committee of conference on the disagreeing votes of the two branches with reference to the House amendment to the Senate relative to pharmaceutical access, costs and transparency (Senate, No. 2520) (amended by the House all after the enacting clause and inserting in place thereof the text of House document numbered 4910; and by striking out the title and inserting in place thereof the following title: “An Act promoting access and affordability of prescription drugs.”),-- reports, a “Bill relative to pharmaceutical access, costs and transparency” (Senate, No. 3012).